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a b s t r a c t
Observational cohort studies in high-income settings have suggested that vaccination order may affect
children’s subsequent risk of a heterologous infection, with live vaccines reducing and inactivated vacci-
nes (given on their own or with a live vaccine), increasing the risk. We used the self-controlled case-series
method, which automatically controls for the individual level confounding to which such cohort studies
are prone, to test this hypothesis. We compared the relative incidence (RI) of infections post-vaccination
in two calendar periods in England; in Period 1 (September 2002–August 2006) live measles, mumps,
rubella (MMR) vaccine was given on its own and in Period 2 (September 2006–April 2010) inactivated
vaccines (7-valent pneumococcal conjugate vaccine (PCV7) and sometimes the combined Haemophilus
influenzae type b/meningococcal group C vaccine (Hib-MenC)) were given concomitantly with MMR.
Admissions for an infection of the upper or lower respiratory tract, gastrointestinal system or other site
in children aged 11–23 months were selected from the Hospital Episode Statistics database in England
and linked to child health immunisation histories. The analysis included a total of 24,144 infections in
21,067 children in Period 1 and 36,880 in 31,616 children in Period 2. The RI of admission for any infec-
tion in Period 1 was 1.00 (95% confidence interval 0.95–1.06) compared with 0.95 (95% confidence inter-
val 0.90–1.00) in Period 2. Comparing the two periods showed no evidence of a difference in the relative
incidence estimates with a ratio of RI of 0.94 (95% confidence interval 0.87–1.02), RIs within 90 days of
vaccination were 0.94 (0.91–0.97) in Period 1 and 0.94 (0.91–0.97) in Period 2, consistent with a tempo-
rary healthy vaccinee effect. In conclusion, we found no evidence to support the hypothesis that there is a
reduction in heterologous infections after MMR on its own or an increase after MMR given concomitantly
with an inactivated vaccine.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Some studies suggest that vaccines can have non-specific
effects on the immune system such that they change the risk of
contracting unrelated infections that are not targeted by the vac-
cine. Studying such non-specific effects is more complex than
assessing the specific vaccine effect because of the large number
of possible diseases to examine, unclear biological mechanism
and likelihood of finding false associations by chance or through
study bias and confounding.
Studies reporting non-specific effects have focused on overall
mortality largely in a small number of low income countries in
West Africa [1,2] and, more recently, in high-income countries on
heterologous infections [3,4,5]. Some of these studies have
reported beneficial effects for live vaccines such as measles and
BCG and deleterious effects for inactivated vaccines such as the
combined diphtheria, tetanus, pertussis vaccine (DTP), with stron-
ger effects often seen in girls than boys. A specific hypothesis
raised and assessed in these studies is that receiving an inactivated
vaccine with or after a live vaccine is detrimental relative to receiv-
ing live vaccine on its own as the last vaccine in a sequence [4,5,6].
A recent systematic review of largely observational cohort stud-
ies with a mortality outcome found that, while there was some evi-
dence to support non-specific effects, most were subject to a
substantial risk of bias [1,2]. Similarly, bias has been demonstrated
in studies with heterologous infections as the outcome in high
income settings [7]. Since such observational studies rely on differ-
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ences between children in the order or timing in which vaccines
are given they are particularly prone to confounding arising from
individual differences in health status or socio-economic variables
that determine both the exposure and outcome. Use of the self-
controlled case-series (SCCS) method which automatically controls
for such individual differences would provide an ideal method for
controlling for such bias [8].
In England we have previously used the SCCS method to exam-
ine the hypothesis that administration of three live viral vaccines
combined - measles, mumps and rubella (MMR) – might ‘‘overload
the immune system”, at a time when calls were made for single
antigen vaccines during the time of the erroneous MMR and autism
safety concerns [9]. We subsequently reported no increase in hos-
pitalisations for either bacterial or viral infections following MMR
in the second year of life but found an apparent protective effect
in the 30 days post MMR [10]. Since this study was done two inac-
tivated vaccines have been added to the UK schedule, a combined
Haemophilus influenzae type b/Meningococcal group C (Hib-MenC)
vaccine given as a booster and a 7-valent pneumococcal conjugate
vaccine (PCV7) given as two priming doses in infancy with a later
booster. These two booster vaccines were recommended to be
given either at the same time as, or for Hib-MenC, prior to MMR.
Using the SCCS method, we have therefore updated our previous
study to test the hypothesis that the risk of heterologous infections
is higher when MMR is given with an inactivated vaccine than on
its own.
2. Methods
2.1. Design
The study design was a self-controlled case-series [8] in which
the relative incidence of hospitalised infections in a time period
when MMR vaccine was given alone is compared to a period when
MMR was given with PCV7 or with both PCV7 and the combined
Hib-MenC vaccine. This comparative SCCS method has been used
previously to compare reactions following acellular and whole cell
pertussis vaccines [11] and is depicted in Fig. 1.
2.2. Case selection
We defined cases as children aged 11 to 23 months with a hos-
pital admission in England (based on national hospital episode
statistics (HES) data [12]) for an infection during the period
01/09/2002 and 30/04/2010 that were linked on NHS number to
vaccine data from the Careplus child health immunisation system
(CHIS), representing approximately 20% of the population in Eng-
land. The areas using CHIS were geographically dispersed and
included 17 of the 152 Primary Care Trusts across the country, cov-
ering parts of the South, South-West, Midlands and North-West of
England. We identified infections based on ICD codes in any of the
20 HES diagnostic fields (supplementary Table S1) and grouped
them into all infections, upper respiratory tract infections (URTI),
lower respiratory tract infections (LRTI), gastrointestinal infections
(gastro) and other infections (other). These codes covered those
used previously [8,9] with additional codes similar to those used
by Sorup et al, encompassing a wide range of bacterial and viral
infections (excluding infections that are commonly vertically
transmitted, or that are characterised by a longer incubation period
such as Mycobacterium tuberculosis) [3]. Where more than one
event was coded on the same day we used the event in the earliest
diagnostic field. We excluded events occurring within 14 days of a
previous event as these were likely to be part of the same infection
episode. To facilitate capture of ongoing infection episodes, we
extracted events from birth to 23 months before restriction to 11
to 23 months.
Fig. 1. Schematic showing the self-controlled case-series method for estimating the ratio of relative incidence (rRI) between the two periods with examples of person time for
3 cases in each period.
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2.3. Exposure
After linkage to the CHIS data we only retained those cases with
a record of MMR given from age 11–23 months. Cases whose MMR
vaccination was between September 2002 and August 2006 were
allocated to Period 1 and those whose MMR vaccination was
between September 2006 and April 2010 were allocated to Period
2. These two periods reflect those in which MMR was scheduled to
be given on its own (Period 1) and with PCV7 and sometimes Hib-
MenC (Period 2). We chose the overall study period to coincide
with CHIS data availability and to have a similar length with each
schedule. The end of Period 2 also coincided with the change from
PCV7 to the13-valent PCV in September 2010. For Period 1 we only
retained individuals who received MMR vaccine and no other vac-
cine aged 11–23 months. For Period 2 we only retained individuals
who received MMRwith PCV7. We also dropped cases in Period 2 if
they received other vaccines with the exception of Hib-MenC
which they could have either at the same time as MMR and
PCV7 or prior to MMR and PCV7, but not after. The vaccine sched-
ule used in England across the study period is shown in supple-
mentary Table S2. We did not make any selection based on
receipt of primary vaccinations, but almost all children will have
received the recommended primary infant schedule comprising
DTP-containing vaccines given with MenC, and in Period 2 also
with PCV7. Children are called for vaccination at around the rec-
ommended age in England by an appointment letter, with remin-
ders sent for non-attenders. Age at MMR vaccination for the CHIS
overall and those with the same vaccine inclusion and exclusion
criteria as used for the study populations in Period 1 and 2 was
similar (supplementary Fig. S1).
2.4. Statistical methods
The hypothesis being tested was that the relative incidence of
infections following MMR alone was the same as when MMR
was given with PCV7 or with PCV7 and Hib-MenC. In testing this
hypothesis, we also, as a secondary aim, tested the hypotheses that
infection incidence is the same following each of the vaccinations
compared to the period prior to MMR or prior to Hib-MenC if this
was given earlier than MMR. The SCCS method uses a conditional
Poisson model to estimate the relative incidence (RI) within indi-
viduals of the outcome of interest (here, hospitalised infections)
in designated post-vaccination risk intervals compared to person-
time outside these intervals. The post-vaccination risk window
we chose was (a) any time (up to age 23 months) after MMR vac-
cination, and (b) within 90 days following MMR vaccination. In
Period 2 those who received a Hib-MenC vaccine prior to MMR/
PCV7 had an additional risk interval extending from the date of
Hib-MenC to the day before MMR/PCV7. The period outside the
risk windows comprised person time before vaccination for the
analysis looking at RI at any time post vaccination, and, in addition,
person time beyond 90 days for the analysis looking at the 90-day
risk window. To estimate the ratio of RI (rRI) between the two time
periods, we created an indicator variable for the Period (1 or 2) and
then estimated the interaction term of this with the post-MMR risk
time (Fig. 1). We adjusted for age using thirteen 28 day intervals
and one 31 day interval by including it as a factor in the model.
We only included person time from 11 to 23 months of age
because prior to 11 months MMR and Hib-MenC vaccines are not
given and infection rates change with age which would mean per-
son time at an earlier age would be uninformative. Since the age of
vaccination varied little over the study period we did not expect
confounding by season (calendar month) or year (September-
August from 2002/03 to 2009/2010), but we did check for this in
the main analyses assessing relative incidence at any time after
vaccination. To assess effect modification by gender we assessed
whether the RI estimates differed by gender for each period using
an interaction term. In sensitivity analyses we, (i) excluded infec-
tion codes that may have a component that is attributable to
measles, mumps, rubella, pneumococcal, Haemophilus influenza b
or meningococcal C infection for which there could be a protective
effect of MMR, Hib-MenC or PCV vaccines, (ii) used weekly age
adjustment and, (iii) just included in Period 2 those who received
MMR/PCV7 and Hib-MenC on the same day. All analyses were done
in Stata version 13 [StataCorp, College Station, TX].
3. Results
Fig. 2 shows how cases were selected for inclusion in the study.
The final number of hospitalisations was 24,144 infection episodes
in 21,067 children for Period 1 and 36,880 infection episodes in
31,616 children for Period 2. The average follow-up time per indi-
vidual was 395 days in period 1 and 360 days in period 2. Of the
31,616 children, 29,410 had Hib-MenC in Period 2, of whom
1,100 had Hib-MenC at the same time as MMR and PCV7 and
28,310 received Hib-MenC before MMR/PCV7. The numbers of
each event grouping in each period used in the SCCS analyses are
shown in Table 1 along with the gender of the individuals and
age. Events were more common in boys and decreased fairly uni-
formly with age, although more rapidly in Period 2.
The results of the SCCS analysis are shown in Table 2. Following
MMR given on its own (Period 1) the RI of infections did not differ
from unity, with the exception of a small decreased risk when
restricting to the window within 90 days of MMR receipt. When
MMRwas given with PCV7 (Period 2) the RI also did not differ from
unity with the exception of the 90-day risk window for all infec-
tions and a 21% decreased risk of a LRTI at any time post- vaccina-
tion before 24 months of age. Comparing the two periods showed
no evidence of a difference in the RI estimates post-MMR for any
analysis. In the second period the relative incidence post Hib-
MenC was also close to one but, as with in the period shortly after
MMR, the relative incidence was just below one for all infections in
the interval between Hib-MenC and MMR and for LRTI where there
was a 12% decreased risk. In the sensitivity analysis, excluding
infections for which there may be a specific effect of vaccination
led to dropping 1314 episodes in Period 1 and 1567 in Period 2,
most of which were LRTI episodes (1154 and 1338 in Period 1
and 2 respectively). The ‘‘all infections” results remained similar
but the reductions post vaccination for LRTI events in Period 2
became less and non-significant (Table 3). Results were similar
when adjusting for age weekly (Table 3). Furthermore, adjusting
for year within each period or for calendar month did not change
relative incidence estimates for all events post MMR by more than
5% so these time-varying factors were not included in the models.
There was no evidence of effect modification on the post-MMR RI
by gender in either period (ratio of RI in males vs. females = 0.98
(95% confidence interval (CI): 0.92–1.04, p = 0.43) for Period 1
and 1.01 (95%CI: 0.96–1.07, p = 0.64) for Period 2).
4. Discussion
In this paper we have used the self-controlled case-series
method, which eliminates bias arising from individual confound-
ing factors that affect both exposure and outcome, to test whether
the RI of infections following vaccination differs if MMR is given
with inactivated vaccines (PCV7 and sometimes Hib-MenC) com-
pared with on its own. From other studies [4,5] the hypothesised
direction of the RI would be that it is greater if MMR is given with
inactivated vaccines and we find no evidence to support this. None
of the RIs for Period 2 when MMR was given with PCV7 were sig-
nificantly different from those in Period 1 when MMRwas given on
N. Andrews et al. / Vaccine 37 (2019) 5211–5217 5213
its own. There was no evidence of an increased risk of infections
after any vaccination nor of any gender-specific differences, nor
that MMR on its own decreased the subsequent risk of a heterolo-
gous infection in the second year of life.
The 5–6% reduction in all-cause infections within 90 days of
MMR given either alone or concomitantly with PCV7, or in the
short interval between Hib-MenC and MMR/PCV7, is consistent
with a temporary healthy vaccinee effect caused by children being
more likely to be taken for vaccination when they are well than
when incubating an illness. This temporary healthy vaccine effect
has been previously documented in the week after MMR vaccine
or a placebo in a randomised double-blind study [13] and also in
the week after DTP vaccine with either a whole cell or acellular
pertussis component where the relative incidence of diarrhoea
was 25% lower when combining estimates together from day 0
to 8 after vaccine [11]. In a post-hoc analysis we separately looked
at the period a week after vaccination and found significant
25–30% reductions in infections in this week, which when removed
from the 90 day period post MMR increased the RI in the remaining
8–90 day periods for all infections from 0.94 to 0.96 (95% CI: 0.93–
1.00) for period 1 and from 0.94 to 0.98 (0.95–1.01) for period 2.
The 21% reduction in LRTI admissions at any time after MMR/
PCV7 in the main analysis (Table 2) was larger and lasted longer
than would be expected to be due to a temporary healthy vaccinee
effect. However, in the sensitivity analysis where we excluded
codes that may have a pneumococcal-attributable component this
reduction became non-significant, consistent with a specific pro-
tective effect of PCV7 (Table 3). The majority of the excluded codes
in the LRTI category were lobar pneumonia many of which in
young children are likely to be caused by the pneumococcus
[14]. The 12% reduction in LRTIs between Hib-MenC and MMR/
PCV7 also became non-significant when potential vaccine-
preventable codes were excluded.
Our results do not confirm the results of studies conducted in
Denmark by Sorup et al [3,4] using a national linked database
and cohort methodology and with a DTaP-containing vaccine as
the exemplar of an inactivated vaccine. In the study evaluating
the effect of MMR given after or with DTaP-IPV-HIB [4] the major-
Fig. 2. Data linkage and selection of infection episodes for analysis.
5214 N. Andrews et al. / Vaccine 37 (2019) 5211–5217
ity of children received the vaccines in the recommended order –
three doses of DTaP-IPV-Hib in the first year of life followed by
MMR with a small minority receiving the third DTaP-IPV-Hib with
or sometimes after MMR. An increase in the risk of hospital admis-
sion for a LRTI but not other types of infection (eg URTI) was found
for children who received simultaneous MMR and DTaP-IPV-Hib as
their last vaccine compared with those whose last vaccine was
MMR. Adjustment for available clinical, demographic and socioe-
conomic variables reduced the incidence rate ratio (IRR) for LRTIs
from 1.58 (95%CI: 1.41–1.77) to 1.27 (1.13 to 1.42). This raises
the possibility that, despite the adjustment for the available vari-
ables, residual bias or confounding from unmeasured variables
may still be present. In an earlier paper [3] using the same Danish
data set but just comparing children who received the recom-
mended sequence of vaccines with those who received the third
dose of DTaP-IPV-Hib after MMR (4% of the study cohort), the big-
gest effect was seen for URTIs between 11 and 23 months of age
with an adjusted IRR for DTaP-IPV-Hib as the last vaccine com-
pared to MMR of 1.89 (95%CI: 1.30 – 2.76). Thus, the putative
non-specific effects are not consistent within the same birth cohort
and appear to be sensitive to the follow up period chosen.
In the US study using a database of health insurance claims, the
more generic hypothesis was tested, namely that the risk of non-
targeted infections after a live vaccine is lower than after an inac-
tivated vaccine given with or without a live vaccine [5]. Cohort
methodology was used with adjustment for available clinical and
geographical variables and with follow up from 16 to 24 months
of age. In addition to MMR and DTaP the study cohort was eligible
to receive five inactivated vaccines (hepatitis A or B, PCV7, polio
and Hib) and varicella as an additional live vaccine, given with or
separately from MMR. Although MMR was recommended to be
given between 12 and 15 months of age and DTaP between 15
and 18 months, for the other live and attenuated vaccines there
was no recommended schedule that if followed would have
ensured that one or other vaccine was given last. The adjusted
analyses showed a lower risk of any infection when a live vaccine
was the last administered compared with an inactivated vaccine,
hazard ratio 0.50 (95%CI: 0.43–0.57) with a smaller effect if the live
vaccine was given concurrently with an inactivated vaccine, hazard
ratio 0.78 (95%CI: 0.67–0.91); unadjusted hazard ratios were not
presented. However, the factors that determine when or if a child
receives a particular vaccine at a particular time in a complex
Table 1
Description of infection events included in the analysis by period.
Factor Level Period1 MMR
only (N = 24,144)
Period2 MMR with
PCV7 (N = 36,880)
Infection Category Gastrointestinal 5092 7858
LRTI 3361 5053
URTI 9043 12,817
Other 6648 11,152
Gender Female 10,655 16,233
Male 13,489 20,647
Age (4 week intervals) 335 to 362 days 2137 3848
363 to 390 days 2099 3666
391 to 418 days 2049 3512
419 to 446 days 1865 3332
447 to 474 days 1945 3095
475 to 502 days 1850 2873
503 to 530 days 1768 2652
531 to 558 days 1609 2435
559 to 586 days 1621 2319
587 to 614 days 1591 2064
615 to 642 days 1422 1961
643 to 670 days 1453 1804
671 to 698 days 1305 1572
699 to 730 days 1430 1747
LRTI = lower respiratory tract infections; URTI = upper respiratory tract infections
Table 2
SCCS analysis of the relative incidence of infections following MMR vaccination given on its own (Period 1) or with PCV7 (Period 2), and following Hib-MenC vaccination (Period
2).
Events Period 1 Vaccine
(risk window)
Period 1
events
Period1 RI
(95% CI)
Period 2 Vaccine
(risk window)
Period 2
events
Period 2 RI
(95% CI)
Period 2:Period1
rRI (95% CI)
All Hib-MenC (to MMR/PCV7) 6017 0.94 (0.90–0.98)
MMR (to age 23 m) 16,127 1.00 (0.95–1.06) MMR/PCV7* (to age 23 m) 22,078 0.95 (0.90–1.00) 0.94 (0.87–1.02)
All Hib-MenC (to MMR/PCV7) 6017 0.94 (0.90–0.97)
MMR (within 90 days) 5671 0.94 (0.91–0.97) MMR/PCV7* (within 90 days) 8903 0.94 (0.91–0.97) 1.00 (0.95–1.05)
Gastro Hib-MenC (to MMR/PCV7) 1316 0.99 (0.89–1.09)
MMR (to age 23 m) 3279 0.93 (0.83–1.04) MMR/PCV7* (to age 23 m) 4621 0.92 (0.81–1.04) 0.99 (0.84–1.17)
URTI Hib-MenC (to MMR/PCV7) 2032 0.97 (0.90–1.05)
MMR (to age 23 m) 6289 1.06 (0.97–1.15) MMR/PCV7* (to age 23 m) 7959 1.05 (0.96–1.16) 1.00 (0.88–1.13)
LRTI Hib-MenC (to MMR/PCV7) 859 0.88 (0.78–0.99)
MMR (to age 23 m) 2122 0.95 (0.83–1.09) MMR/PCV7* (to age 23 m) 2788 0.79 (0.68–0.91) 0.83 (0.68–1.01)
Other Hib-MenC (to MMR/PCV7) 1810 0.90 (0.83–0.98)
MMR (to age 23 m) 4437 1.02 (0.92–1.12) MMR/PCV7* (to age 23 m) 6710 0.93 (0.84–1.03) 0.92 (0.80–1.05)
RI = relative incidence; rRI = ratio of relative incidences.
* Also given with Hib-MenC for about 3% of vaccinations.
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schedule such as that in the US are not known and are unlikely to
be completely controlled for by variables included in the adjusted
analyses. Thus, as stated by the authors themselves ‘‘the extent of
potential biases from confounding and selection bias is unknown”.
Caution in the interpretation of observational studies which
rely on children in the same birth cohort receiving vaccines for
unknown reasons in different sequences or at different ages was
advised by the authors of a population based cohort study in the
Netherlands [7]. The recommended schedule in the study was
DTaP-IPV-Hib at 2, 3, 4 and 11 months followed by MMR given
at the same time as the inactivated meningococcal C conjugate
vaccine (MenC) at 14 months. The hazard ratio for the risk of an
admission for an infection adjusted for a range of infant, parental
and household variables when MMR and MenC vaccines were
given last compared with when the last dose was the fourth
DTaP-IPV-Hib was 0.62 (95% CI: 0.57–0.67) consistent with a
higher risk after a DTaP-containing vaccine. However, there was
also a reduced risk of infection when children who had received
their fourth dose of DTaP-IPV-Hib vaccine were compared with
those who at a similar age had only received a third dose. This sug-
gests that timely receipt of a recommended dose may be a marker
of a child with a generally more healthy constitution, or possibly
other unmeasured confounders, and that such biases may explain,
at least in part, non-specific effects of vaccines that appear to
depend on which type of vaccine was delivered last.
In our analyses we used the SCCS method in which cases serve
as their own controls with each case’s observation period being
divided into a pre-defined post-vaccination risk period or a control
period. The method was first developed to assess adverse reactions
to vaccines and automatically controls for individual confounding
variables such as clinical, behavioural or socio-economic factors
that do not vary with time and, in the case of non-specific effect
studies, may predispose to hospital admission for an infection
and also determine when or if a particular vaccine is given (i.e. vac-
cinees being generally more healthy as described in the Dutch
study) [7]. Unlike cohort studies in which residual bias and con-
founding may still be present even in adjusted analyses, our SCCS
analyses is not affected by such biases. Moreover, in our study
the comparison between the RI of infection after MMR given alone
or concurrently with an inactivated vaccine was the result of a
change in national policy that resulted in MMR being the last vac-
cine given in Period 1 and MMR plus an inactivated vaccine in Per-
iod 2. The minority of children who for reasons unknown did not
adhere to the recommended schedule could be excluded from
the analysis whereas in the cohort studies within the same birth
cohort they comprised the comparator group.
Despite the advantages of the SCCS method there are limita-
tions. Whilst we adjust for the major time-varying confounder of
age, other time-dependent factors may operate, such as a
temporary healthy vaccinee effect. However, this would be inde-
pendent of vaccine given which is consistent with our findings.
Vaccine deferral after an event that occurs close to the time of
scheduled vaccination can lead to a small over-estimation of the
RI when using the SCCS method [15]. Further work is required to
assess this bias when using long risk windows, but any such bias
would not be expected to have a differential affect in the two peri-
ods so should not affect the rRI estimates. Our study compares
schedules using different time periods. Whilst the method is not
affected by differing incidence between the periods there were
some differences in the distribution of the type of infection such
that the all infections analysis involved a different distribution of
infections in the two periods. Also, the exclusions due to receipt
of other vaccines in the second year of life (or MMR not given with
PCV in Period 2) differs between periods. We did not validate the
accuracy of any of the diagnostic codes used in the analysis but
neither was code validation done in the Danish or US cohort stud-
ies and it seems unlikely that the specificity of the clinical coding in
HES was so much lower than in these other studies as to mask a
non-specific effect. Indeed, HES codes were recently used to assess
the impact of PCV7 vaccination on a range of non-specific infec-
tions and showed a clear relationship between expected specificity
of the code for a pneumococcal-attributable infection and magni-
tude of impact [16]. In the UK national immunisation schedule
no booster dose of DTaP is offered in the second year of life so
we were unable to assess the specific effect of this inactivated vac-
cine on the risk of heterologous infections.
In conclusion our SCCS study provides no evidence to support
the hypothesis that inactivated vaccines given on their own, or
concurrently with a live vaccine, increase the risk of a non-
targeted infection compared with administration of a live vaccine
on its own, nor that MMR vaccine on its own decreases the risk.
While our study was conducted in a high income setting and can-
not necessarily be extrapolated to resource poor settings with high
mortality, it is important that there is objective evaluation of the
potential for bias and confounding in observational studies wher-
ever they are conducted and recognition that this may still be pre-
sent when using conventional cohort or case control methods
despite adjustment for measured potential confounders.
5. Ethical permissions
Public Health England is able to process identifiable data under
Regulation 3 of The Health Service (Control of Patient Information)
(Secretary of State for Health, 2002). This is for purposes related to
communicable diseases and other risks to public health and
includes the delivery, efficacy and safety of immunisation pro-
grammes and adverse reactions to vaccines and medicines. To
Table 3
SCCS analysis of the relative incidence of infections following MMR vaccination given on its own (Period 1) or with PCV7 (Period 2), and following Hib-MenC vaccination (Period
2). Sensitivity analysis results.
Analysis* Period 1 Vaccine
(risk window)
Period 1
events
Period1 RI
(95% CI)
Period 2 Vaccine
(risk window)
Period 2
events
Period2 RI
(95% CI)
Period2:Period1
rRI (95% CI)
Possible vaccine preventable
infections excluded
Hib-MenC (to MMR/PCV7) 5777 0.95 (0.91–1.00)
MMR (to age 23 m) 15,227 1.01 (0.96–1.06) MMR/PCV7** (to age 23 m) 21,145 0.96 (0.91–1.02) 0.96 (0.89–1.03)
LRTI events, Possible vaccine
preventable infections excluded
Hib-MenC (to MMR/PCV7) 649 0.96 (0.84–1.10)
MMR (to age 23 m) 1327 0.95 (0.81–1.12) MMR/PCV7** (to age 23 m) 1996 0.87 (0.73–1.03) 0.91 (0.72–1.15)
Age adjusted using weekly
intervals
Hib-MenC (to MMR/PCV7) 6017 0.93 (0.89–0.98)
MMR (to age 23 m) 16,127 1.01 (0.96–1.06) MMR/PCV7** (to age 23 m) 22,078 0.94 (0.89–1.00) 0.93 (0.87–1.01)
Just those in period 2 getting
all 3 vaccines together
MMR (to age 23 m) 16,127 1.00 (0.95–1.06) MMR/PCV7/Hib-MenC
only (to age 23 m)
2110 1.02 (0.91–1.15) 1.02 (0.90–1.15)
* The default model has all events included, 4-week age adjustment, follow up to 23 months with risk window to the end of follow-up, all pre-vaccination person time
included in the control period and no exclusion of possible vaccine component infections.
** Also given with Hib-MenC for about 3% of vaccinations. RI = relative incidence; rRI = ratio of relative incidence.
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